2018 Update and 2019 Outlook Given at the CPHI Conference

/in , /by

Estelle® Oral Contraception programme on track – US/CANADA Phase III arm due to complete in Q4 2018; partnering discussions ongoing including for us market Preparations for Phase III Donesta® trials moving ahead, including co-partnering discussions Further Marketing authorisations obtained for MyRing™ Liège, Belgium, 10 October 2018 – 20:30 CEST – Mithra (Euronext Brussels: MITRA), a […]

Read more →

Notice of 2018 Extraordinary General Meeting Regarding Proposed Warrant Plan

/in , /by

Liège, Belgium, 5 October 2018 – 7:30 CEST – Mithra (Euronext Brussels: MITRA), a company specialized in Women’s Health, today announces its intention to hold an Extraordinary General Meeting (“EGM”) on the 5 November 2018 at 11:00 am in Flémalle, 57 rue de l’Expansion (Belgium). The meeting will consider a new warrant plan whereby a […]

Read more →

Presentation of Donesta® PhIIb Results at the 2018 Annual Meeting of the North American Menopause Society

/in , /by

Liège, Belgium, October 3nd 2018 – Mithra (Euronext Brussels: MITRA), a company specialized in Women’s Health, today announces its Phase IIb results for Donesta® will be presented at the 29th Annual Meeting of the North American Menopause Society (NAMS), being held on 3-6 October 2018 in San Diego, CA.  

Read more →

Mithra Signs Exclusive License and Supply Agreement for the Commercialization of Myring™ in Chile with Laboratorio Pasteur

/in , /by

Liège, Belgium, 26 September 2018 – 7:30 CEST – Mithra (Euronext Brussels: MITRA), a company specialized in Women’s Health, is pleased to announce the finalization and signature of the contract with Laboratorio Pasteur S.A., a Chilean pharmaceutical company also devoted to women’s health, for an exclusive License and Supply Agreement (LSA) to commercialize Myring™ in […]

Read more →

Mithra Announces 2018 Half Year Results

/in , /by

Liège, Belgium, 25 September 2018 – 7:30 CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announces its financial results for the six-month period ending 30 June 2018, prepared in accordance with IFRS. The full interim report is available on the Investors section of the website.  

Read more →

Mithra Finalizes Contract for the Commercialization of Estelle® with South Korean Women’s Health Leader Hyundai Pharm

/in , /by

Liège, Belgium, 24 September 2018 – 7:30 CEST – Mithra (Euronext Brussels: MITRA), a company specialized in Women’s Health, is pleased to announce the finalization and signature of the contract with Hyundai Pharm, a South Korean Women’s Health leader, for an exclusive license and supply agreement to commercialize Estelle® in South Korea. The signature follows the […]

Read more →

Mithra Signs Exclusive License and Supply Agreement for Commercialization of Tibelia® in Taiwan

/in , /by

Liège, Belgium – 21 September 2018, 07:30 CEST – Mithra Pharmaceuticals (Euronext Brussels: MITRA), a company specialized in Women’s Health, today announced that it has entered into an exclusive license and supply agreement with Pei Li Pharmaceutical Industrial Co, Ltd (“Pei Li Pharm”) to commercialize Tibelia® in Taiwan.

Read more →

Mithra and Richter Sign License and Supply Agreement for Commercialization of Estelle®, a Novel Oral Contraceptive

/in , /by

Liège, Belgium – 12 September 2018, 7:30 CEST – Mithra Pharmaceuticals (hereinafter: “Mithra”) and Gedeon Richter Plc. (hereinafter: “Richter”) today announced that they have entered into a license and supply agreement to commercialize Estelle®, a combined oral contraceptive (COC), containing 15 mg Estetrol (E4) / 3 mg drospirenone (DRSP), in Europe and Russia. Richter will commercialize […]

Read more →

Mithra Announces Positive Top-Line Results of Estelle® Phase III Oral Contraceptive Study in EU/Russia

/in , /by

Primary efficacy endpoint indicates excellent contraceptive efficacy, with a Pearl Index (PI) of 0.48 per 100 women, exceeding efficacy goals Key secondary endpoints achieved, including outstanding bleeding profile, cycle control, quality of life and safety and tolerability Estelle® Phase III stsudy in US/Canada on track to report top-line results in Q1 2019 Data further support Estelle® as […]

Read more →

Mithra Announces Belux Agreement with Ceres Pharma Worth over EUR 40 Million

/in , /by

Mithra to receive EUR 20 million upon signing, with further EUR 20 million in potential additional earn-outs Agreement covers the sale of the Women’s Health branded generics business in Belgium and Luxembourg as well as License and Supply agreements for certain Mithra assets in the region Divestment of BeLux portfolio in line with Mithra’s strategy […]

Read more →